Community/Retail

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses its medication access framework for quality measurement during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

The approval of R2 is based on data from the phase 3 AUGMENT study evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously-treated FL and MZL.

Effective treatment with ART has increased the life span of people living with HIV, but they remain at risk for chronic diseases.

The new indication makes cariprazine (Vraylar, Allergan and Gedeon Richter) the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes, according to the companies.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.

What is causing the visual distrubances in this young man?

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's origins as a measure developer during the PQA Annual Meeting in Baltimore, MD.

Ruxolitinib is the first and only FDA-approved treatment for this indication, according to Incyte, the drug's manufacturer.

Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and how they complement existing measures during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

The study included an analysis detailing crash and traffic violation records for newly licensed drivers. It is the first large-scale longitudinal study on this topic.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

PQA is described as a "a neutral convener of a multistakeholder base."

Understanding what constitutes a 'good' immune response to HIV may provide important information for vaccine design and intervention.

NKTR-181 is currently under review with the FDA, with a Prescription Drug User Fee Act (PDUFA) target action expected in August 2019.

According to the ADA, best practice is to pack at least twice as much medications and glucose testing supplies as normally needed to minimize complications due to travel delays or lost luggage.3 Many manufacturers of insulin pumps will provide a loaner for international travel.

Calcipotriene foam was approved by the FDA in 2010 for patients age 18 years and older.

Norris Turner, PharmD, PhD, vice president of Strategic Alliances and Measures at PQA discusses the uses of PQA's measures in Medicaid during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Regulatory affairs is another frontier for pharmacists to explore, and pharmacists are just scratching the surface of the opportunities in this area. In this interview with pharmacist Brendan Doran of CTI Clinical Trial & Consulting, he touches on the many phases of the drug life cycle with an emphasis on the process of bringing a drug to regulatory bodies for market approval, and gives a look into some of the current and emerging roles available in regulatory affairs.

Results of study demonstrate safety profile in pediatric patients.

The number of cases of the disease in 2016 was the highest since 1972 and represents a decades-long trend.

This ad was supported by Church & Dwight Co. Inc., featuring Feryal Hajee, MD.

The new phase 2 data for an investigational once-daily, fixed dose combination currently in development for the treatment of inadequately controlled asthma was presented at the 2019 Annual International Congress of the American Thoracic Society (ATS) in Dallas.

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the current landscape of medication quality during the PQA Annual Meeting in Baltimore, MD.

The acquisition agreement with Peloton includes the drug candidate PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).

Solifenacin succinate tablet is a muscarinic antagonist indicated to treat this condition, with symptoms of urgency, urge urinary incontinence, and urinary frequency.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains the role of genomics in prostate cancer.

The drug is indicated for seizures that are distinct from a patient's usual seizure pattern, in individuals age 12 years and older with epilepsy.